Literature DB >> 23792104

Adverse drug reactions induced by valproic acid.

Radu M Nanau1, Manuela G Neuman.   

Abstract

Valproic acid is a widely-used first-generation antiepileptic drug, prescribed predominantly in epilepsy and psychiatric disorders. VPA has good efficacy and pharmacoeconomic profiles, as well as a relatively favorable safety profile. However, adverse drug reactions have been reported in relation with valproic acid use, either as monotherapy or polytherapy with other antiepileptic drugs or antipsychotic drugs. This systematic review discusses valproic acid adverse drug reactions, in terms of hepatotoxicity, mitochondrial toxicity, hyperammonemic encephalopathy, hypersensitivity syndrome reactions, neurological toxicity, metabolic and endocrine adverse events, and teratogenicity.
Copyright © 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADR; AED; AHS; ALP; ALT; AST; Adverse drug reactions; Alpers-Huttenlocher syndrome; CI; CYP; DRESS; Drug monitoring; HHV; Hepatocytotoxicity; IQ; MELAS; Mitochondrial toxicity; OR; POLG; SCAR; SJS; Stevens–Johnson syndrome; TEN; VPA; Valproic acid; adverse drug reaction; alanine aminotransferase; alkaline phosphatase; antiepileptic drug; aspartate aminotransferase; confidence interval; cytochrome p450; drug reaction with eosinophilia and systemic symptoms; human herpes virus; intelligence quotient; mitochondrial DNA polymerase γ; mitochondrial myopathy, encephalopathy, lactic acidosis and stroke; odds ratio; severe cutaneous adverse reaction; toxic epidermal necrolysis; valproic acid; γ-GTP; γ-glutamyl transpeptidase

Mesh:

Substances:

Year:  2013        PMID: 23792104     DOI: 10.1016/j.clinbiochem.2013.06.012

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  75 in total

Review 1.  An update and review of the treatment of myoclonus.

Authors:  Kelly Mills; Zoltan Mari
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

2.  Novel Mechanisms of Valproate Hepatotoxicity: Impaired Mrp2 Trafficking and Hepatocyte Depolarization.

Authors:  Dong Fu; Panli Cardona; Henry Ho; Paul B Watkins; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2019-07-31       Impact factor: 4.849

Review 3.  Creating a "Prosurvival Phenotype" Through Histone Deacetylase Inhibition: Past, Present, and Future.

Authors:  Ihab Halaweish; Vahagn Nikolian; Patrick Georgoff; Yongqing Li; Hasan B Alam
Journal:  Shock       Date:  2015-08       Impact factor: 3.454

4.  Treatment of Convulsive Status Epilepticus.

Authors:  Eric H Grover; Yara Nazzal; Lawrence J Hirsch
Journal:  Curr Treat Options Neurol       Date:  2016-03       Impact factor: 3.598

5.  Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.

Authors:  Mikko Gynther; Lauri Peura; Monika Vernerová; Jukka Leppänen; Jussi Kärkkäinen; Marko Lehtonen; Jarkko Rautio; Kristiina M Huttunen
Journal:  Neurochem Res       Date:  2016-07-14       Impact factor: 3.996

Review 6.  Inherited mitochondrial genomic instability and chemical exposures.

Authors:  Sherine S L Chan
Journal:  Toxicology       Date:  2017-07-26       Impact factor: 4.221

7.  Valproic acid disrupts the oscillatory expression of core circadian rhythm transcription factors.

Authors:  Chanel A Griggs; Scott W Malm; Rosa Jaime-Frias; Catharine L Smith
Journal:  Toxicol Appl Pharmacol       Date:  2017-12-08       Impact factor: 4.219

8.  Intermittent activation of notch signaling promotes bone formation.

Authors:  Yaoting Ji; Yongxin Ke; Song Gao
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

Review 9.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 10.  Stem cell-derived liver cells for drug testing and disease modeling.

Authors:  Matthew D Davidson; Brenton R Ware; Salman R Khetani
Journal:  Discov Med       Date:  2015-05       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.